Clinical trials: Cirrhosis Portal
Esophageal Neoplasms, Cirrhosis
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors.
- Conditions
- Esophageal Neoplasms, Cirrhosis, Portal Hypertension
- Trial name
- NCT04994548
- Testing
- Endosocpic resection of early esophageal tumor
- Volunteers
- 112 people
- Sponsor
- Central Hospital, Nancy, France
Liver Cirrhosis, Acute-On-Chronic Liver Failure
Characterization and Pathogenesis of ACLF
This single-center prospective observational study aims at characterization of pathogenesis of ACLF. There will be three different cohorts investigated with the main endpoint mortality in these groups. 1.
- Conditions
- Liver Cirrhosis, Acute-On-Chronic Liver Failure, Portal Hypertension
- Trial name
- ACLF-I (NCT04975490)
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital
Liver Cirrhosis, Portal Hypertension
The Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis
This study is a prospective, multi-center and observational clinical study. Investigators would like to explore the optimal emergency endoscopy timing in cirrhosis patients with esophagogastric variceal bleeding (EGVB) by…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Esophageal Varix Bleeding
- Trial name
- NCT04932200
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Renmin Hospital of Wuhan University
Liver Cirrhosis, Hypertension, Portal
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
- Trial name
- PPIs (NCT03175731)
- Testing
- Proton Pump Inhibitors
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Yanjing Gao
Liver Cirrhosis, Portal Vein Thrombosis
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
- Trial name
- NCT04173429
- Testing
- Nadroparin calcium, warfarin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Qilu Hospital of Shandong University
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Liver Diseases, Portal Hypertension
TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites
Transjugular intrahepatic portosystemic shunt (TIPS) could effectively decrease portal hypertension-related complications. This study intends to evaluate the efficacy and safety of TIPS combined with subsequent microwave ablation…
- Conditions
- Liver Diseases, Portal Hypertension, Cirrhosis, Liver, Ascites
- Trial name
- NCT04640116
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), microwave ablation (MWA)
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Advanced Chronic Liver Disease, Surgery--Complications
Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery
The ELASTO-SURGERY study aims to evaluate the prognostic role of portal hypertension evaluated by non-invasive methods in predicting post-operative morbidity (at 90 days) and mortality (at 365 days) in patients with advanced…
- Trial name
- NCT04615091
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Cirrhosis, Liver Failure
Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List
It is a cohort to evaluate the power of different diagnostic tests in predicting the prognosis of patients with severe liver disease.
- Conditions
- Cirrhosis, Liver Failure, Portal Hypertension
- Trial name
- NCT01774617
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Guilherme Rezende
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Cirrhosis, Portal Hypertension
Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis
The aim of this study is to investigate the effects of spironolactone on liver fibrosis progression and portal pressure gradient in patients with advanced chronic liver disease.
- Trial name
- FP-PH (NCT02907749)
- Testing
- Spironolactone and carvedilol, Carvedilol
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Changqing Yang
End-stage Liver Disease (ESLD), Liver Transplant
A Physical Activity Program in End-state Liver Disease
The primary aim of this study is to improve both physical fitness and sarcopenia of patients with ESLD who are potentially eligible for liver transplantation through a 12-week physical training program.
- Conditions
- End-stage Liver Disease (ESLD), Liver Transplant, Sarcopenia, Poor Physical Fitness
- Trial name
- NCT02776553
- Testing
- Nutritional consultation, Physical training program, Behavioral modification therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Liver Cirrhosis, Peptic Ulcer
Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis
Proton pump inhibitor plus propranolol versus proton pump inhibitor alone on peptic ulcer healing in patients with liver cirrhosis: a randomized trail
- Trial name
- PU (NCT04140591)
- Testing
- Proton-pump inhibitor, Propranolol+Proton-pump inhibitor
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hypertension, Portal, Liver Cirrhosis
Outcome After TIPS
This clinical trial is a retrospective single-centre study. Research data will be acquired via patient histories stored in the hospital data system.
- Conditions
- Hypertension, Portal, Liver Cirrhosis, Variceal Hemorrhage, Ascites Hepatic
- Trial name
- NCT03459378
- Testing
- no intervention - retrospective analyses
- Where
- Austria
- Volunteers
- 158 people
- Sponsor
- Medical University of Graz
Cirrhosis Portal
Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Decompensated cirrhosis is associated with sarcopenia. TIPS is an efficient treatment of portal hypertension. Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes…
- Trial name
- Gluco-TIPS (NCT04387058)
- Testing
- TIPS
- Where
- France
- Volunteers
- 111 people
- Sponsor
- University Hospital, Toulouse
Liver Cirrhosis Portal
Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
Clinical trial to compare the effects of terlipressin and octreotide in the reduction of portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis
- Trial name
- INFUTER (NCT04353193)
- Testing
- Terlipressin, Octreotide
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Juan A. Arnaiz
Portal Hypertension, Cirrhosis
Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS
The aim of this study is to investigate the possibilities of early and precise management to decrease portal vein pressure in cirrhotic patients, guided by a non-invasive 3D-virtual-model of hepatic portal system (3D-vHPS).
- Trial name
- NCT02925975
- Testing
- Carvedilol, 3D-vHPS, Routine endoscopic procedures
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Changqing Yang
Coagulation Disorder, Cirrhosis, Liver
ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension
Hemostasis-related disorders are common in cirrhosis and portal hypertension. However, it is not known whether the net effect of changes in hemostasis in the sense of predisposition to hemorrhagic or thrombotic state.
- Trial name
- NCT04267406
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Portal Hypertension, Cirrhosis
Surrogate Markers of Portal Pressure
This is a prospective longitudinal study that will evaluate if changes (pre and post therapy) in indocyanine green (ICG) retention test and liver stiff ness (LS) and spleen stiffness (SS) as measured by acoustic radiofrequency…
- Trial name
- NCT02508298
- Testing
- HVPG, Indocyanine Green Retention test, Liver stiffness measurement
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- VA Connecticut Healthcare System
Portal Hypertension, Liver Fibroses
Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness
Pilot study examining changes in liver stiffness measured by ultrasound before and after TIPS creation
- Trial name
- NCT03352882
- Testing
- Ultrasound
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pennsylvania